Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 2:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 199 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Advanced Solid Tumor or Lymphoma Clear all
Completed Phase 1 Interventional

APG-115 in Patients With Advanced Solid Tumors or Lymphomas

NCT02935907
View directory record Official record
Conditions
Patients With Advanced Solid Tumor or Lymphoma
Interventions
APG-115
Drug
Lead sponsor
Ascentage Pharma Group Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Grand Rapids, Michigan • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Oct 4, 2026, 2:58 PM EDT
Completed Phase 1 Interventional

Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma

NCT00734890
View directory record Official record
Conditions
Lung Cancer, Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bevacizumab, vandetanib, laboratory biomarker analysis, pharmacological study
Biological · Drug · Other
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 16, 2012 · Synced Oct 4, 2026, 2:58 PM EDT
Completed Phase 1 Interventional

Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas

NCT03311412
View directory record Official record
Conditions
Metastatic Cancer, Solid Tumor, Lymphoma
Interventions
Sym021, Sym022, Sym023
Drug
Lead sponsor
Symphogen A/S
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
3
States / cities
Grand Rapids, Michigan • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Oct 4, 2026, 2:58 PM EDT
Withdrawn Phase 1 Interventional

Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma

NCT03422874
View directory record Official record
Conditions
Neoplasms, Lymphoma
Interventions
MLN9708, Nelfinavir
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Oct 4, 2026, 2:58 PM EDT
Completed Phase 1 Interventional

A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas

NCT01588678
View directory record Official record
Conditions
Advanced Solid Tumor, Lymphoma
Interventions
DS-3078a
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 4, 2026, 2:58 PM EDT
Active, not recruiting Phase 2 Interventional

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

NCT02568267
View directory record Official record
Conditions
Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms, Lymphoma, Large-Cell, Anaplastic, Melanoma, Neuroendocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Primary Brain Tumors, Renal Cell Carcinoma, Sarcomas, Salivary Gland Cancers, Adult Solid Tumor
Interventions
Entrectinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
48
States / cities
Phoenix, Arizona • Duarte, California • La Jolla, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 4, 2026, 2:58 PM EDT
Completed Phase 1 Interventional

Open-Label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of VELCADE in Patients With Either Advanced Solid Tumors or Non-Hodgkin's Lymphoma.

NCT00298779
View directory record Official record
Conditions
Tumors, Non-Hodgkins's Lymphoma
Interventions
omeprazole and bortezomib
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 6, 2008 · Synced Oct 4, 2026, 2:58 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)

NCT04439279
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Trametinib Dimethyl Sulfoxide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 4, 2026, 2:58 PM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function

NCT02214147
View directory record Official record
Conditions
Advanced Solid Tumors, Relapsed/Refractory Lymphoma
Interventions
Alisertib
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
7
States / cities
Miami, Florida • Chicago, Illinois • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 4, 2026, 2:58 PM EDT
Completed Phase 2 Interventional Results available

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

NCT03526250
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma
Interventions
Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
115
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 4, 2026, 2:58 PM EDT
Completed Phase 1 Interventional

Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease

NCT00364676
View directory record Official record
Conditions
Tumors, Hodgkins Disease, Non-Hodgkins Lymphoma
Interventions
VLI
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2015 · Synced Oct 4, 2026, 2:58 PM EDT
Completed Phase 1 Interventional

Study of the Vascular Disrupting Agent NPI-2358 in Patients With Advanced Solid Tumors or Lymphoma

NCT00322608
View directory record Official record
Conditions
Cancer
Interventions
NPI-2358
Drug
Lead sponsor
Nereus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Detroit, Michigan • San Antonio, Texas • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jan 10, 2011 · Synced Oct 4, 2026, 2:58 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

NCT04195555
View directory record Official record
Conditions
Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent WHO Grade 2 Glioma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory WHO Grade 2 Glioma, Wilms Tumor
Interventions
Ivosidenib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
171
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 4, 2026, 2:58 PM EDT
Terminated Phase 1 Interventional

A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas

NCT01163071
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
ABI-011
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
Detroit, Michigan • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Oct 4, 2026, 2:58 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer

NCT02392611
View directory record Official record
Conditions
Solid Tumors and Lymphomas
Interventions
Alobresib, Exemestane, Fulvestrant
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Scottsdale, Arizona • Fort Wayne, Indiana • Goshen, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Oct 4, 2026, 2:58 PM EDT
Not listed Phase 1 Interventional

Chemotherapy in Treating Young Patients With Recurrent or Refractory Meningeal Leukemia, Lymphoma, or Solid Tumors

NCT00003073
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
liposomal cytarabine
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
1 Year to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
5
States / cities
Los Angeles, California • Stanford, California • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2010 · Synced Oct 4, 2026, 2:58 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

NCT05565417
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cutaneous Squamous Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Small Bowel Cancer, Esophageal Cancer, Colorectal Cancer, Diffuse Large B Cell Lymphoma, Hodgkin Lymphoma, Burkitt Lymphoma, Follicular Lymphoma
Interventions
IMT-009, Fruquintinib
Drug · Combination Product
Lead sponsor
Immunitas Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
9
States / cities
Tucson, Arizona • Denver, Colorado • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 4, 2026, 2:58 PM EDT
Terminated Phase 1 Interventional

Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma

NCT02110563
View directory record Official record
Conditions
Solid Tumors, Multiple Myeloma, Non-Hodgkins Lymphoma, Pancreatic Neuroendocrine Tumors, PNET, NHL
Interventions
DCR-MYC
Drug
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Stanford, California • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Oct 4, 2026, 2:58 PM EDT
Recruiting Phase 4 Interventional

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

NCT07426484
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma, Skin Cancer
Interventions
Cosibelimab, Prednisone, Sirolimus, Everolimus
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 4, 2026, 2:58 PM EDT
Withdrawn Phase 1 Interventional

A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor

NCT03359733
View directory record Official record
Conditions
Lymphoma, Malignant, Advanced Solid Neoplasms
Interventions
TAK-659
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
New Haven, Connecticut • Detroit, Michigan • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 4, 2026, 2:58 PM EDT
Completed Phase 1 Interventional

Phase I Trial of PX-478

NCT00522652
View directory record Official record
Conditions
Advanced Solid Tumors, Lymphoma
Interventions
PX-478
Drug
Lead sponsor
Cascadian Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Scottsdale, Arizona • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 4, 2026, 2:58 PM EDT
Completed Phase 1 Interventional

S0355 Ixabepilone in Treating Patients With Advanced Solid Tumors or Lymphomas and Liver Dysfunction

NCT00049400
View directory record Official record
Conditions
Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
BMS-247550
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
23
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2015 · Synced Oct 4, 2026, 2:58 PM EDT
Completed Phase 1 Interventional

A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma.

NCT01237236
View directory record Official record
Conditions
Advanced Solid Tumor, Lymphomas
Interventions
LEE011
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
4
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 4, 2026, 2:58 PM EDT
Terminated Phase 1 Interventional Results available

Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants

NCT04167137
View directory record Official record
Conditions
Metastatic Solid Neoplasm, Lymphoma
Interventions
SYNB1891, Atezolizumab
Drug
Lead sponsor
Synlogic
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
6
States / cities
Aurora, Colorado • Hackensack, New Jersey • Columbus, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 4, 2026, 2:58 PM EDT